Pam Barker | Director of TLB Europe Reloaded Project
What is being reported here as ‘Oxford University’ is one and the same as the Oxford Vaccine Group.
We remind readers of Robert F. Kennedy’s report on the recent Oxford Vaccine Group’s spike-protein vaccine trials (Another Gates Vaccine Bites the Dust … Sick Monkeys Everywhere!). Gates seems to be banking on at least two vaccines – the Moderna one (an mRNA vaccine), which ran into serious trouble during recent trials (see Vaccine Trial Catastrophe: Moderna Vaccine has 20% ‘Serious’ Injury Rate in High Dose Group) and the Oxford Vaccine Group’s. However, as the report on the Oxford vaccine trials shows, the macaque monkeys that made up the trial subjects a) didn’t show antibodies after the vaccine, then b) got sick when exposed to the coronavirus.
In what universe are the governments of 4 EU countries committing billions in taxpayer money to dispense this so far dubious vaccine to the tune of 400 million doses (there are over 500 million people in the EU)? From the Big Pharma perspective, of course, they’ll get the guaranteed revenue they’re looking for. According to our calculations, a vaccine that may run at 300 pounds/dollars/euros – a typical sum for a vaccine, multiplied by 400 million (for the EU), garners 1.2 billion for AstraZeneca. The article mentions 300 million doses for the US. That will make 900 million for AZ. US and EU distribution alone will reap around 2 billion based on these calculations. Globally, the sums are jawdropping:
The Anglo-Swedish company recently completed similar agreements with Britain, the United States the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance for 700 million doses. A license also has been agreed with the Serum Institute of India for another 1 billion doses.
China, Brazil, Japan and Russia have also expressed interest, Soriot said. (France24)
From this Sputnik News report, titled Europe’s Covid Vaccine Race: France, Germany, Italy and the Netherlands Sign AstraZeneca Contract, the four EU countries have formed an ‘Inclusive Vaccine Alliance,’ which will be open to other EU countries joining in. Of note:
The researchers at AstraZeneca have started a large-scale clinical trial in which the vaccine will be tested on 10,000 people. An additional trial with 30,000 participants will take place later this month.
AstraZeneca has also secured a deal with two US government agencies and Vanderbilt University to create antibodies to be used to treat and prevent Covid-19, according to Bloomberg.
Notice how that taxpayer bill may go up significantly:
However, according to the Guardian, AstraZeneca’s CEO, Pascal Soriot, could not guarantee the vaccine would work and said several would be required, though he expressed confidence.
In a normal universe, what doesn’t work or cannot be guaranteed to work would be abandoned and not purchased! Further,
He added that the Alliance is also holding discussions with other pharmaceutical companies as it is still uncertain if AstraZeneca’s vaccine will go into production.
We remind readers of a piece we published a while back showing that attempts to stop the coronavirus or COMMON COLD VIRUS by way of a vaccine have been tried and failed. See The Pink Elephant in the Room regarding COVID-19 and that ‘Vaccine’. Unless, as the author reminds us, this engineered virus has been designed for a vaccine to actually work…
Italy, Germany, France & Netherlands sign deal for up to 400 million Oxford Covid-19 vaccines – Italian health minister
Four EU countries have signed a contract with pharmaceutical company AstraZeneca to produce enough Oxford University vaccines to rid the continent of Covid-19 infections, the Italian health minister said.
Under the agreement, British-Swedish pharmaceutical giant AstraZeneca will produce up to 400 million doses of the vaccine, which is enough for “the whole population of Europe,” Roberto Speranza wrote on Facebook.
The minister said that trials for the vaccine, which was developed by Oxford University, are set to be completed this fall, and the first doses will be available by the end of the year.
“The vaccine is the only definitive solution to Covid-19,” he wrote. (ER: Which we know to be a lie.)
AstraZeneca has a deal with the US government to supply the country with 300 million doses of the vaccine. Earlier this week, the company signed an agreement with American firm Emergent BioSolutions to be its manufacturing partner in the US.
Various nations and companies have been racing to develop a vaccine for the novel coronavirus, which has infected more than 7.6 million people globally, and killed over 426,000, according to Johns Hopkins University.
Published to The Liberty Beacon from EuropeReloaded.com
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.